Table 2 Data in patients with and without hepatic steatosis
Hepatic steatosis | Hepatic steatosis | p value | |
|---|---|---|---|
Yes | No | ||
n = 35 | n = 25 | ||
Age at biopsy (yrs) | 39.0 ± 8.9 | 40.0 ± 7.2 | ns |
Age at HIV diagnosis (yrs) | 32.9 ± 8.9 | 34.0 ± 6.8 | ns |
Male | 32 (91%) | 22 (88%) | ns |
ethnicity | 14 (40%) | 9 (36%) | ns |
Weight (kg) | 74.2 ± 9.2 | 69.7 ± 10.8 | 0.74 |
Weight > 75 kg | 17 (48%) | 7 (28%) | ns |
Diabetes mellitus | 2 (6%) | 1 (4%) | ns |
Alcohol | 11 (31%) | 7 (28%) | ns |
Antiretroviral therapy | |||
No therapy | 10 (28%) | 7 (28%) | ns |
NRTI | 7 (20%) | 3 (12%) | ns |
Duration (mths) | 22.3 ± 18.8 | 21.7 ± 12.4 | ns |
HAART only | 9 (26%) | 13 (52%) | 0.037 |
Duration (mths) | 30.4 ± 27.3 | 29.5 ± 27.1 | ns |
Sequential | 9 (26%) | 2 (8%) | 0.08 |
Duration (mths) | 92.8 ± 37.2 | 106.0 | ns |
Received PI | 13 (37%) | 8 (32%) | ns |
Received NNRTI | 14 (40%) | 10 (40%) | ns |
Received stavudine | 12 (34%) | 5 (20%) | ns |
Received didanosine | 8 (23%) | 5 (20%) | ns |
Received zidovudine | 21 (60%) | 12 (48%) | ns |
Time from HIV diagnosis to HAART (mths) | 47.4 + 38.7 | 40.4 + 50.9 | ns |
CD4 count (/mm3) | 410 (110–1100) | 490 (100–1200) | ns |
HIV VL (copies/ml) | UD (UD-210955) | 70 (UD-121843) | ns |
HCV VL (IU/ml) | 441309 (2716–769231) | 1286755 (29451–14975540) | ns |
Non 1 genotype | 6/21 (28%) | 6/21 (28%) | ns |
Cholestrol | 4.3 ± 1.2 | 4.1 ± 1.08 | ns |
HDL | 1.1 ± 0.5 | 1.1 ± 0.3 | ns |
Triglyceride | 2.2 ± 2.0 | 1.5 ± 0.6 | ns |
Cholestrol/HDL ratio | 4.8 ± 2.2 | 3.8 ± 1.0 | ns |
Fasting blood glucose | 6.1 + 6.4 | 5.1 ± 0.9 | ns |
ALT (IU/L) | 131 + 149.8 | 104 ± 74.6 | ns |
Fibrosis stage | 3.0 ± 1.9 | 2.5 ± 1.7 | ns |
NI grade | 3.7 ± 1.9 | 3.7 + 1.7 | ns |
Cirrhosis | 12 (34%) | 3 (12%) | 0.049 |